Earnings Summary

Evelo Biosciences Inc’s net profit jumped 30.95% since last year same period to $-21.1Mn in the Q2 2023. On a quarterly growth basis, Evelo Biosciences Inc has generated 15.76% jump in its net profits since last 3-months.

Evelo Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.28 - a 15.15% jump from last quarter’s estimates.

Evelo Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.28.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Evelo Biosciences Inc’s return on assets (ROA) stands at -0.85.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Evelo Biosciences Inc’s return on equity (ROE) stands at -62.33.